EBS-Lassa / Emergent Biosolutions - LARVOL DELTA

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa fever. (PubMed, Vaccine) - "Together, these studies supported a first-in-human dose-escalation, safety, and immunogenicity clinical study. This paper uses a viral vector vaccine safety template developed by the Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) Working Group to review the features of the rVSV-vectored EBS-LASV vaccine candidate and provides a high-level summary of safety findings from preclinical studies and the Phase 1 clinical study."

Benefit-risk assessment • Journal • Infectious Disease

Preclinical Safety Assessment of the EBS-LASV Vaccine Candidate against Lassa Fever Virus. (PubMed, Vaccines (Basel)) - "No toxicity was observed in rabbits receiving a three-dose regimen of EBS-LASV. These studies demonstrate that EBS-LASV is safe when administered to animals and supported a first-in-human dose-escalation, safety, and immunogenicity clinical study."

Journal • Preclinical • Infectious Disease

Lassa fever vaccine candidates: A scoping review of vaccine clinical trials. (PubMed, Trop Med Int Health) - "Though LF vaccine development is still in early stages, current progress towards a safe and effective vaccine is encouraging."

Journal • Review • Infectious Disease